Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open Label, Randomized Phase II Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-risk Neuroblastoma

NCT01467986 is registered in ClinicalTrials.gov with University of Regensburg as lead sponsor.

NCT NCT01467986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01467986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open Label, Randomized Phase II Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-risk Neuroblastoma
Lead sponsor
University of Regensburg
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
September 30, 2020
Enrollment
130 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma recurrent